Canaccord initiated coverage of Alterity Therapeutics (ATHE) with a Speculative Buy rating and $A1.6c price target Alterity is developing ATH434 for the treatment of synucleinopathy-driven neurodegenerative diseases such as multiple system atrophy and Parkinson’s disease, the analyst tells investors in a research note. The firm says ATH434 addresses an unmet need.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHE:
- Alterity ‘never lost sight’ of interest in Parkinson’s disease, CEO says
- Alterity CEO says to meet with FDA, move forward with Phase 3 study
- Alterity ‘really emerging’ as U.S. company, CEO tells The Fly
- Stamler says Alterity treating neurodegeneration in ‘way no one else is doing’
- Meet Alterity Therapeutics: Fly exclusive interview with CEO David Stamler